Search
ASCO 2026: Immatics is presenting data on its second generation PRAME targeting cell therapy in gynecological cancers and synovial sarcoma
CEO Harpreet Singh walks us though the data and reminds us how this second generation approach uses CD4+ helper T-cells in addition to CD8 for additional firepower.
May 30
From Germany: U.S. listed Immatics was founded in Tubingen and is based on foundational work on PRAME that was done here. A pivotal analysis is scheduled to be triggered this year
Co-Founder & CEO Harpreet Singh walks us through the science of PRAME, which happened here at the University of Tubingen and led to the work the company does today. A pivotal trial for a cell therapy in melanoma will trigger an analysis this year, and Immatics also has bispecific programs and a second generation cell therapy under development.
Apr 27
With a phase 3 trial for its PRAME cell therapy underway and a data update coming up at ASCO, Immatics is pushing to be a leader in TCR based cell therapies and T-cell engagers
CEO Harpreet Singh joins us from the company's office in Munich, Germany, where he describes the founding of the company and previews...
May 9, 2025
SITC 2024: Immatics CEO Harpreet Singh shares an update on clinical data presented at SITC for the company's Gen 1 and Gen 2 PRAME cell therapies
He describes the Gen 1 data in melanoma and more, and compares it to what we have seen with competitor TIL data. Also, why the Gen 2...
Nov 9, 2024
.png){kind=logo}
